1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Lanzhou Foci Pharmaceutical Co., Ltd. Class A

Lanzhou Foci Pharmaceutical Co., Ltd. Class A

SSZSE:002644
7.72
CNY
+0.01
(+0.13%)
3.48BMarket Cap
Lanzhou Foci Pharmaceutical Co., Ltd. Class A
SZSE:002644
(Shenzhen Stock Exchange)

Recent

price

7.72

P/E

ratio

- -

div

yld

0.25%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.79
0.81
0.6
0.66
1.11
0.69
0.71
0.98
1.07
1.23
1.31
1.6
2.04
2.28
1.92
1.79
- -
Revenue per Share
0.15
0.1
0.07
0.07
0.1
0.09
0.12
0.15
0.14
0.14
0.21
0.18
0.21
0.13
0.12
0.1
- -
Basic EPS, GAAP
0.1
-0.2
-0.28
-0.22
0.13
0.03
-0.41
-0.74
-0.44
-0.09
-0.12
-0.04
0.09
0.08
0.05
0.32
- -
Free Cash Flow per Basic Share
0.01
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.06
0.12
0.01
0.05
0.03
0.01
0.02
Dividend per Share
0.98
1.46
1.52
1.58
1.65
2.42
2.53
2.66
2.82
2.95
3.1
3.16
3.37
3.42
3.51
3.59
3.65
Book Value per Share
0.76
1.27
1.33
1.39
1.32
2.18
2.29
2.41
2.58
2.79
2.94
3.01
3.2
3.24
3.34
3.43
3.49
Tangible Book Value per Share
332
334
444
444
358
472
511
511
511
511
511
511
511
511
511
510
511
Basic Weighted Avg Shares
262
271
266
292
399
328
363
501
545
629
668
818
1,042
1,163
980
916
- -
Sales/Revenue/Turnover
14.27
13.8
11.79
11.08
5.23
5.29
9.39
11.92
11.39
10.95
8.39
10.83
15.38
8.47
10.84
13.75
- -
Operating Margin (%)
11
13
14
15
15
18
19
21
34
53
45
49
50
52
51
55
- -
Depreciation Expense
51
32
30
31
35
43
61
74
73
71
108
93
109
67
60
49
- -
Net Income, GAAP
8.02
11.66
12.04
14.43
11.93
12.5
13.69
15.2
15.68
9.92
17.48
15.61
16.35
16.56
10.81
27.8
- -
Effective Tax Rate (%)
19.53
11.82
11.4
10.5
8.68
13.11
16.77
14.78
13.39
11.31
16.17
11.41
10.42
5.78
6.13
5.37
- -
Profit Margin (%)
111
392
335
360
455
923
1,284
727
419
552
632
660
761
771
842
892
929
Working Capital
2
2
2
- -
- -
- -
108
598
387
80
- -
1
1
1
3
8
10
LT Debt
326
648
676
703
735
1,234
1,291
1,359
1,440
1,507
1,587
1,628
1,741
1,768
1,815
1,855
1,883
Total Equity
8.52
5.02
3.28
2.86
3.18
3.66
4.26
4.31
3.82
4.06
6.55
5.73
6.96
3.92
3.55
2.66
- -
Return on Invested Capital (%)
16.13
6.51
4.69
4.5
4.75
4.39
4.63
4.42
3.86
4.2
6.79
5.75
6.38
3.79
3.26
2.78
- -
Return on Capital (%)
17.69
6.58
4.59
4.44
4.82
4.36
4.83
5.59
5.21
4.83
7
5.83
6.52
3.88
3.4
2.72
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
38
20
22
LT Borrowings
6
6
7
LT Finance Leases
2
2
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
511
511
511
Market Capitalization
4,412
4,519
3,478

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,333
1,363
1,422
Cash, Cash Equivalents & STI
524
565
635
Accounts Receivable, Net
302
324
339
Inventories
290
294
308
Total Current Liabilities
441
448
494
Payables & Accruals
- -
- -
- -
ST Debt
38
20
22
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.18%
3.19%
2.23%
Free Cash Flow
-171.3%
23.79%
543.7%
Net Income, GAAP
4.73%
-12.8%
-18.08%
Sales/Revenue/Turnover
11.84%
7.83%
-6.6%
Total Cash Common Dividend
- -
39.81%
-55.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
274
225
210
272
980
2025
216
213
- -
291
916
2026
212
229
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.01
0.04
0.12
2025
0.04
0.02
- -
0.02
0.1
2026
0.04
0.03
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
0.01
- -
- -
0.01
2026
- -
0.02
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
LanZhou Foci Pharmaceutical Co.,Ltd. engages primarily in the research, development, production, and sales of traditional Chinese medicines and health products. The company produces a wide range of proprietary Chinese medicines including Liuwei Dihuang Pills, Xiaoyao Pills, Erchen Pills, Incense Stomach Nourishing Pills, Angong Gyuhuang Pills, Ejiao, Fufang Huangqi Jianpi Oral Liquid, Xiangsha Yangwei Pills, Shenrong Guben Huanshao Pills, and donkey-hide gelatin, covering therapeutic categories such as tonics, cold remedies, gastrointestinal treatments, gynecology, and tranquilizing sleep aids. Additionally, it cultivates and sells Chinese herbal medicines and processes Chinese medicine tablets under brands including Min Shan and Foci. The company exports its products to over twenty-seven countries, including the United States, Canada, Japan, and several Southeast Asian and Oceanian markets. LanZhou Foci Pharmaceutical was founded in 1929 in Shanghai, relocated to Lanzhou in 1956, and is headquartered in Lanzhou New Area, Gansu Province. It is a state-owned listed company on the Shenzhen Stock Exchange since 2011. Recently, LanZhou Foci Pharmaceutical has pursued new drug research and registration projects targeting class 3.1 new drugs, planning to develop three classical traditional Chinese medicine formula preparations aimed at promoting innovation and inheritance in the industry. The company is also conducting secondary research and development on exclusive specialty products such as Shenrong Guben Shaowan, Compound Astragalus Jianpi Oral Liquid, and Shugan Xiaojidan to enhance clinical value and market competitiveness. On the corporate front, in 2023, Gansu Provincial State-owned Asset Investment Group completed a strategic acquisition of a significant stake in LanZhou Foci Pharmaceutical, reinforcing its state-backed ownership. Operationally, the company has relocated manufacturing activities to Lanzhou New Area as part of strategic industrial upgrading. Financially, the company reported mixed results for 2024 and Q1 2025, with revenue declines but gains in net income attributable to shareholders. The company continues to focus on leveraging its nearly 100-year legacy as a key traditional Chinese medicine manufacturer in northwestern China while expanding its product pipeline and enhancing market presence through innovation and state-backed investment support. These developments reflect LanZhou Foci Pharmaceutical's commitment to combining traditional medicine heritage with modern pharmaceutical research and expanding both its domestic and international footprint in the healthcare sector.